|本期目录/Table of Contents|

[1]姜雪莲 综 述,姚逸临 审 校.髓源抑制性细胞的临床研究[J].天津医科大学学报,2020,26(01):96-99.
点击复制

髓源抑制性细胞的临床研究(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
26卷
期数:
2020年01期
页码:
96-99
栏目:
综述
出版日期:
2020-04-06

文章信息/Info

Title:
-
文章编号:
1006-8147(2020)01-0100-04
作者:
姜雪莲 综 述姚逸临 审 校
(上海中医药大学附属龙华医院肿瘤科,国家中医临床研究基地,上海 200032)
Author(s):
-
关键词:
髓源抑制细胞恶性肿瘤免疫
Keywords:
-
分类号:
R1
DOI:
-
文献标志码:
A
摘要:
自2010年始恶性肿瘤已经成为主要的致死原因,据统计我国每天有7 500例癌症患者死亡。免疫治疗作为一种很有前途的抗癌治疗手段,确实是一个突破,特别是对于免疫检查点抑制剂的发现,然而,大多数抗癌免疫治疗由于肿瘤介导的免疫逃避和免疫抑制仍然无效,如骨髓来源的一群异质性细胞-髓源抑制细胞(MDSCs),是树突状细胞、巨噬细胞及粒细胞的前体,具有显著抑制免疫细胞应答的能力,可通过多种机制抑制机体的抗肿瘤免疫而参与肿瘤的进展,因此,通过靶向MDSCs进行抗肿瘤治疗成为近年来研究的热点。本文就MDSCs与恶性肿瘤的关系、促肿瘤转移机制及当前的临床研究进行综述。
Abstract:
-

参考文献/References:

[1] Balkwill F,Mantovani A. Inflammation and cancer: back to Virchow[J].Lancet,2001,357(9255):539
[2] Gabrilovich D I,Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009,9(3):162
[3] Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity[J]. Cancer Immunology Immunotherapy,2010,59(10):1593
[4] Ma J,Xu H,Wang S. Immunosuppressive role of myeloid-derived suppressor cells and therapeutic targeting in lung cancer[J]. J Immunol Res,2018 :6319649. doi: 10.1155/2018/6319649
[5] Mandruzzato S,Brandau S,Britten C M,et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study[J]. Cancer Immunol Immunother,2016,65(2):161
[6] Hoechst B,Ormandy L A,Ballmaier M A,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells[J]. Gastroenterology,2008,135(1):234
[7] Bronte V,Brandau S,Chen S H,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J]. Nat Commun,2016,7:12150
[8] Serafini P. Myeloid derived suppressor cells in physiologi-cal and pathological conditions: the good, the bad,and the ugly[J]. Immunol Res, 2013,57(1/3):172
[9] Lin Y,Yang X,Liu W,et al. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSCs accumulation[J]. Oncogene,2017,36(25):3599
[10] Gabrilovich D,Nefedova Y. ROR1C regulates differentiation of myeloid-derived suppressor cells[J]. Cancer Cell,2015,28(2):147
[11] Gao J,Wu Y,Su Z,et al.Infiltration of alternatively activated macrophages in cancer tissue is associated with MDSCs and Th2 polarization in patients with esophageal cancer[J]. PLoS One,2014, 9(8):e104453
[12] Filipazzi P,Huber V,Rivoltini L.Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients[J].Cancer Immunol Immunother,2012,61(2):255
[13] Talmadge J E,Gabrilovich D I.History of myeloid-derived suppressor cells[J]. Nat Rev Cancer,2013,13(10):739
[14] 韩凌斐,郭晓青,胡家昌,等.宫颈癌患者外周血髓源性抑制细胞的比例及其临床意义[J].华中科技大学学报:医学版,2015, 44(1):32
[15] Gonda K,Shibata M,Ohtake T,et al.Myeloid-deriver suppressor cells are increased and correlated with type 2 immune responses,malnutrition,inflammation,and poor prognosis in patients with breast cancer[J]. Oncol Lett,2017,14(2):1766
[16] 杜伟娇,于津浦,李慧,等.乳腺癌患者肿瘤组织中髓源抑制性细胞的临床意义[J]. 中国肿瘤生物治疗杂志,2010,17(5):545
[17] 李晓宁.髓源性抑制细胞在胃癌肿瘤免疫中的作用[J]. 临床医药文献杂志,2016,3(4):654
[18] Zhang B,Wang Z,Wu L,et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma[J]. PLoS One,2013,8(2):e57114
[19] 奉松青,刘春晓,郑少波,等.肾癌患者外周血中CD33+HLA-DR-髓源抑制性细胞的表达及其临床意义[J]. 南方医科大学学报,2013,33(4):550
[20] 李艳丽,卜庆.外周T细胞淋巴瘤患者外周血中髓源抑制性细胞的表达及意义[J]. 天津医药,2015,43(3):282
[21] 安晓华,王波,薛邦禄.外周血中髓源性抑制细胞比例与非小细胞肺癌患者临床分期及免疫功能的关系[J]. 中国肿瘤临床与康复,2016,23(3):274
[22] Tian X Y,Ma J,Wang T,et al. Long Non-Coding RNA HOXA transcript antisense RNA Myeloid-Specific 1-HOXA1 axis downregulates the immunosuppressive activity of Myeloid-Derived suppressor cells in lung cancer[J]. Front Immunol,2018,9:473
[23] Jordan K R,Kapoor P,Spongberg E,et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients[J]. Cancer Immunol Immunother,2017,66(4):503
[24] Ouzounova M,Lee E,Piranlioglu R,et al. Monocytic and granulocytic myeloid derivedsuppressor cells differentially regulate spatiotemporal tumour plasticityduring metastatic cascade[J]. Nat Commun,2017,8: 14979
[25] Bronte V. Zanovello P regulation of immune responses by l-arginine metabolism[J]. Nat Rev Immunol,2005,5(8):641
[26] Srivastava M K,Sinha P,Clements V K,et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[J]. Cancer Res,2010,70(1):68
[27] Corzo C A,Cotter M J,Cheng P Y,et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells[J]. J Immunol,2009,182(9):5693
[28] Nagaraj S,Gupta K,Pisarev V,et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer[J]. Nat Med,2007,13(7):828
[29] Huang B,Pan P Y,Li Q,et al. Gr-1+CD115+immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells andT-cell anergy in tumor-bearing host[J]. Cancer Res,2006,66(2):1123
[30] 黄香,吴昊,郭人花. 顺铂对荷瘤鼠髓源性抑制细胞的选择性下调作用[J].中华临床医师杂志:电子版,2013,7(20):9226
[31] 徐扬.温阳通滞中药治疗晚期胃癌阳虚证疗效及对炎症免疫细胞因子,外周血髓源性抑制细胞,调节性T细胞水平的影响[J].现代中西医结合杂志,2017,26(33):3684
[32] 靖林林,陈继跃,姚学清,等. 岭南中药龙术消瘤方对结直肠癌免疫抑制微环境的影响[J]. 新中医,2014,46(7):140
[33] 柴旺,何小鹃,朱军璇,等. 黄芪多糖对B16-F10荷瘤鼠髓样抑制细胞免疫活性的影响[J]. 中国中医基础医学杂志,2012,18(1):63
[34] 吴皓,李鸿,祁鑫,等. 八宝丹对结肠癌荷瘤小鼠的血、脾和骨髓中的髓系抑制性细胞的影响[J]. 中华中医药杂志,2014,29(2):568

相似文献/References:

[1]孙干成,侯永强,高 杰,等.PHF20相互作用蛋白质组学分析及其在肿瘤中的作用研究[J].天津医科大学学报,2019,25(06):563.
 SUN Gan-cheng,HOU Yong-qiang,GAO Jie,et al.A study of proteomic analysis of the PHF20 interactome and its role in tumorigenesis[J].Journal of Tianjin Medical University,2019,25(01):563.

备注/Memo

备注/Memo:
基金项目 上海市科委科研计划资助项目(15401931200);上海市卫健委临床研究专项(201940144)
作者简介 姜雪莲(1994-),女,硕士, 住院医师,研究方向:肺癌的中医药治疗;通信作者:姚逸临,E-mail:yaoyilinsh@sina.com。
更新日期/Last Update: 2020-04-16